162 related articles for article (PubMed ID: 36557000)
21. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.
Zhou D; Chen W; Cheng H; Qiao JL; Zhu LL; Li ZY; Xu KL
Leuk Res; 2018 Jun; 69():1-6. PubMed ID: 29609040
[TBL] [Abstract][Full Text] [Related]
22. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
23. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
24. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
25. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
Lee HS; Park LC; Lee EM; Lee SJ; Shin SH; Im H; Do KM; Kim EJ; Ye BJ; Song MK; Kim SH; Lee SM; Lee WS; Kim YS
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):70-5. PubMed ID: 22088920
[TBL] [Abstract][Full Text] [Related]
26. Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study.
Saelue P; Thongsukhsai P
J Thromb Thrombolysis; 2023 Apr; 55(3):527-535. PubMed ID: 36652138
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Analysis of Gene Mutation and Vascular Events in Patients with BCR/ABL Negative Myeloproliferative Neoplasms].
Hu BD; Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):813-818. PubMed ID: 35680810
[TBL] [Abstract][Full Text] [Related]
28. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
[TBL] [Abstract][Full Text] [Related]
29. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Randi ML; Rossi C; Fabris F; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
[TBL] [Abstract][Full Text] [Related]
30. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
[TBL] [Abstract][Full Text] [Related]
31. DETERMINING THE RISK OF THROMBOSIS AMONG THE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA.
Ghirdaladze D; Vatsadze T; Kirtava T
Georgian Med News; 2020 Feb; (299):143-146. PubMed ID: 32242862
[TBL] [Abstract][Full Text] [Related]
32. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
34. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study.
Prajs I; Kuliczkowski K
Adv Clin Exp Med; 2017; 26(1):115-121. PubMed ID: 28397442
[TBL] [Abstract][Full Text] [Related]
36. Prediction of major bleeding events in 1381 patients with essential thrombocythemia.
Stuckey R; Ianotto JC; Santoro M; Czyż A; Encinas MMP; Gómez-Casares MT; Pereira MSN; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Sobas MA
Int J Hematol; 2023 Nov; 118(5):589-595. PubMed ID: 37660316
[TBL] [Abstract][Full Text] [Related]
37. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
38. Developments in diagnosis and treatment of essential thrombocythemia.
Mora B; Passamonti F
Expert Rev Hematol; 2019 Mar; 12(3):159-171. PubMed ID: 30793984
[TBL] [Abstract][Full Text] [Related]
39. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
40. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
Palandri F; Polverelli N; Catani L; Ottaviani E; Baccarani M; Vianelli N
Ann Hematol; 2011 Aug; 90(8):933-8. PubMed ID: 21287350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]